Strategic external intelligence for pharmaceuticals, life sciences and biotechnology

The challenge

A sudden spike in negative sentiment around a flagship product put our client under pressure to treat it as a safety issue, triggering the full weight of a recall response.

The solution

Polecat’s real-time intelligence traced the surge to reputational and perception-based drivers, not a verified product defect.

The result

The company redirected its response to reputation management, avoiding the cost and disruption of an unwarranted recall while still addressing the underlying concern.

External risk intelligence is the continuous measurement of risks that reach a pharmaceutical company from outside: regulatory action, safety and clinical controversy, pricing and reimbursement pressure, supply chain disruption and reputational damage. Polecat provides this as Strategic External Intelligence for pharmaceuticals, life sciences and biotechnology, scoring each risk out of 100 with a timeline and a probability, benchmarked against peers and projected three to six months ahead, with every score traceable to its sources. How Polecat works

Polecat follows the FDA, EMA, MHRA and other national regulators from early commentary and advisory committee discussion through to formal action, alongside the clinical community, scientific press and patient advocacy groups. Each development is scored for severity, velocity, authority and reach against a client’s products and pipeline, so a safety concern gaining regulatory attention is distinguished from one that is contained. Coverage includes clinical trial registries, scientific journals, trade press and regulatory dockets across 195 countries.

Yes. Polecat traces a surge in negative attention to its drivers, which shows whether it is grounded in verified safety evidence or in perception, commentary and campaign activity. In one case, a global pharmaceutical manufacturer facing pressure to recall a flagship product used Polecat to establish that the drivers were reputational rather than a product defect, redirected its response to reputation management and avoided an unwarranted recall while still addressing the underlying concern. The reputation and communications view

Polecat provides early warning on pricing pressure, reimbursement decisions and reform, from US drug price negotiation and state-level action to European health technology assessment and national reimbursement decisions. Policy movement is scored for direction and velocity by market and by therapeutic area, so market access teams can see where a reform is gathering momentum before it reaches a formal decision. Peer benchmarking shows whether scrutiny is focused on a client’s portfolio or spread across the class.

Yes. Polecat scores late-stage assets and marketed products for regulatory, safety and reputational risk, drawing on clinical trial registries, scientific and medical press, regulatory commentary and investor and analyst discussion. Escalation around a trial, an indication or a competitor’s comparable asset is flagged early and benchmarked against how similar events developed. Polecat does not interpret clinical data; it measures external attention and risk around it.

Yes. Polecat provides an outside-in view of a target’s regulatory, safety, pricing and reputational exposure before capital is committed, independent of the target’s own disclosures. The target is scored on the same basis as the acquirer and its peers, with history backfilled from the archive, so business development teams can see whether external risk is building or resolving and how it compares with alternatives. The evidence trail supports due diligence documentation.

Polecat provides a live, quantified read on how patient groups, clinicians, payers and the public are responding to a client’s products, pricing or controversies, and whether each issue is resolving or growing. Voices are scored for authority and reach as well as volume, so a position taken by a leading clinical body is weighted differently from general commentary. Polecat measures conversations and outcomes across external sources; it is not a social media monitoring tool.

No. Pharmacovigilance and medical information systems handle adverse event reporting and regulatory obligations. Polecat sits alongside them as the external intelligence layer, measuring how regulators, clinicians, patients, media and investors are responding to a product and projecting where that attention is heading. Risk, compliance and corporate affairs teams use it to decide when an external issue needs escalation, and to brief the board with quantified, source-traceable evidence.

Polecat scores suppliers, manufacturing sites and sourcing regions for tariff, export control, quality, environmental and geopolitical risk, with early warning of threats to active ingredient supply, manufacturing continuity and patient supply. Coverage includes regulatory inspection records, trade policy, local news and NGO reporting across each sourcing jurisdiction. Procurement and supply chain teams see named exposure by site and by material, with time to impact estimated against comparable past events.

Yes. Polecat is designed to be consumed without a large risk team. Intelligence briefings and alerts are routed to the right people with severity and velocity attached, and board reports are produced on the client’s cadence. Polecat’s sector analysts interpret the data, so a small leadership team receives measured external intelligence without building the capability internally. Engagements typically start with a fixed-scope assessment that calibrates the service to the company’s products, pipeline and markets. Talk to our team